Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ischemia Reperfusion Injury - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Ischemia Reperfusion Injury - Pipeline Review, H2 2016', provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury - The report reviews pipeline therapeutics for Ischemia Reperfusion Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ischemia Reperfusion Injury therapeutics and enlists all their major and minor projects - The report assesses Ischemia Reperfusion Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Ischemia Reperfusion Injury Overview 8 Therapeutics Development 9 Pipeline Products for Ischemia Reperfusion Injury - Overview 9 Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis 10 Ischemia Reperfusion Injury - Therapeutics under Development by Companies 11 Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes 13 Ischemia Reperfusion Injury - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Ischemia Reperfusion Injury - Products under Development by Companies 18 Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes 20 Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 22 Amyndas Pharmaceuticals LLC 22 Angion Biomedica Corp. 23 Biomedica Management Corporation 24 Bolder Biotechnology, Inc. 25 Corline Biomedical AB 26 Curatis Pharma GmbH 27 Erimos Pharmaceuticals, LLC 28 Gilead Sciences, Inc. 29 Ischemix, Inc. 30 Kowa Company, Ltd. 31 LG Life Science LTD. 32 Omeros Corporation 33 Opsona Therapeutics Limited 34 Orexo AB 35 Pharming Group N.V. 36 PledPharma AB 37 Prolong Pharmaceuticals, LLC 38 Proteo, Inc. 39 Prothix BV 40 Recordati S.p.A. 41 Stealth BioTherapeutics Inc. 42 Ischemia Reperfusion Injury - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 47 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 AER-271 - Drug Profile 54 AM/AMBP-1 - Drug Profile 55 ANV-6L15 - Drug Profile 56 APP-103 - Drug Profile 57 BB-3 - Drug Profile 58 BBT-059 - Drug Profile 62 C1 esterase inhibitor (recombinant) - Drug Profile 63 CMX-2043 - Drug Profile 71 CRX-526 - Drug Profile 74 Curaglutide - Drug Profile 75 Des-Asp Angiotensin 1 - Drug Profile 76 Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drug Profile 77 elamipretide - Drug Profile 78 EP-80317 - Drug Profile 85 GS-459679 - Drug Profile 86 hemin (human) - Drug Profile 87 KN-93 - Drug Profile 88 LH-021 - Drug Profile 89 mangafodipir trisodium - Drug Profile 90 MG-53 - Drug Profile 91 mirococept - Drug Profile 93 Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile 94 Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile 95 Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease and Kidney Transplantation - Drug Profile 96 Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 98 NecX - Drug Profile 99 Neutrolide - Drug Profile 100 NP-202 - Drug Profile 101 Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile 102 OMS-721 - Drug Profile 103 OPN-305 - Drug Profile 109 pitavastatin NP - Drug Profile 111 PRO-02 - Drug Profile 112 R-190 - Drug Profile 113 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischemia - Drug Profile 115 Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 116 Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 117 Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile 118 Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 119 Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 120 Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 121 Renaparin - Drug Profile 122 Sanguinate - Drug Profile 123 Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile 125 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 126 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 127 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 128 Small Molecules for Ischemia Reperfusion Injury - Drug Profile 129 Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 130 Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile 131 Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 132 Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 133 Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 134 Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 135 terameprocol - Drug Profile 136 tiprelestat - Drug Profile 138 TMS-007 - Drug Profile 142 UCF-101 - Drug Profile 143 UWA-TAT - Drug Profile 144 VCP-746 - Drug Profile 145 Ischemia Reperfusion Injury - Dormant Projects 146 Ischemia Reperfusion Injury - Discontinued Products 150 Ischemia Reperfusion Injury - Product Development Milestones 151 Featured News & Press Releases 151 Appendix 162 Methodology 162 Coverage 162 Secondary Research 162 Primary Research 162 Expert Panel Validation 162 Contact Us 162 Disclaimer 163
List of Tables
Number of Products under Development for Ischemia Reperfusion Injury, H2 2016 13 Number of Products under Development for Ischemia Reperfusion Injury - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Clinical Stage Development, H2 2016 20 Comparative Analysis by Early Stage Development, H2 2016 21 Products under Development by Companies, H2 2016 22 Products under Development by Companies, H2 2016 (Contd..1) 23 Products under Investigation by Universities/Institutes, H2 2016 24 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 25 Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 26 Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp., H2 2016 27 Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corporation, H2 2016 28 Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology, Inc., H2 2016 29 Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2016 30 Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H2 2016 31 Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals, LLC, H2 2016 32 Ischemia Reperfusion Injury - Pipeline by Gilead Sciences, Inc., H2 2016 33 Ischemia Reperfusion Injury - Pipeline by Ischemix, Inc., H2 2016 34 Ischemia Reperfusion Injury - Pipeline by Kowa Company, Ltd., H2 2016 35 Ischemia Reperfusion Injury - Pipeline by LG Life Science LTD., H2 2016 36 Ischemia Reperfusion Injury - Pipeline by Omeros Corporation, H2 2016 37 Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Limited, H2 2016 38 Ischemia Reperfusion Injury - Pipeline by Orexo AB, H2 2016 39 Ischemia Reperfusion Injury - Pipeline by Pharming Group N.V., H2 2016 40 Ischemia Reperfusion Injury - Pipeline by PledPharma AB, H2 2016 41 Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 42 Ischemia Reperfusion Injury - Pipeline by Proteo, Inc., H2 2016 43 Ischemia Reperfusion Injury - Pipeline by Prothix BV, H2 2016 44 Ischemia Reperfusion Injury - Pipeline by Recordati S.p.A., H2 2016 45 Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Inc., H2 2016 46 Assessment by Monotherapy Products, H2 2016 47 Number of Products by Stage and Target, H2 2016 49 Number of Products by Stage and Mechanism of Action, H2 2016 52 Number of Products by Stage and Route of Administration, H2 2016 55 Number of Products by Stage and Molecule Type, H2 2016 57 Ischemia Reperfusion Injury - Dormant Projects, H2 2016 150 Ischemia Reperfusion Injury - Dormant Projects (Contd..1), H2 2016 151 Ischemia Reperfusion Injury - Dormant Projects (Contd..2), H2 2016 152 Ischemia Reperfusion Injury - Dormant Projects (Contd..3), H2 2016 153 Ischemia Reperfusion Injury - Discontinued Products, H2 2016 154
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
